Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Anesthesiology
    • Trichosporon fungus–...

    Trichosporon fungus– An emerging opportunistic blood stream infection

    Written by Hina Zahid Published On 2019-05-27T19:28:32+05:30  |  Updated On 27 May 2019 7:28 PM IST
    Trichosporon fungus– An emerging opportunistic blood stream infection

    Trichosporon species are the major emerging opportunistic pathogen in immunocompromised patients. They are known to be inhabitants of soil and may colonize human skin, upper respiratory tract and gastrointestinal tract. Its diverse refractoriness to conventional antifungal drugs and association with high mortality rate is worrisome.


    Previously, all pathogenic members of the genus Trichosporon were referred as a single species, T. beigelii.3 Biochemical and morphologic differences within the genus had led to new nomenclature of T. beigelii into 9 distinct species, amongst them Trichosporon asahii is the most common cause of disseminated disease. Phenotypic identification of Trichosporon species usually gives very inconsistent results, so molecular methods are required for accurate identification, but they are still expensive and not suitable for most laboratories.


    In the past, amphotericin B was recommended for treatment but the response was poor and the failure rate was high. Even MICs of echinocandins are very high and multiple incidences of breakthrough infections have been reported. Trichosporon species are usually susceptible to azoles thus, treatment should be done using one of these azoles.


    Dr Meera Challapilla and colleagues at PD Hinduja Hospital, Mumbai, Maharashtra conducted a study to determine the risk factors, treatment outcome and antifungal susceptibility pattern of Trichosporon species in bloodstream infections. The Study has appeared in the Journal of Association of Physicians of India.


    The researchers evaluated all patients with blood culture positive for Trichosporon species from January 2012 to August 2016 at PD Hinduja National Hospital and research centre retrospectively. Species identification and antifungal susceptibility by broth microdilution method for various drugs were determined using Vitek2 compact automated system.


    They found 12 patients to have Trichosporon bloodstream infection. 9 isolates that were speciated all were T. asahii. All patients had a central venous catheter and received prior antibiotics. The overall mortality rate was 50%.


    The researchers concluded that higher mortality was associated with central venous catheter and voriconazole should be used as a drug of choice for treatment. Identification of Trichosporon species along with its sensitivity and proper treatment of patients is of utmost importance.


    Trichosporon species is an emerging fungal infection which can be easily misidentified as Candida. But dry wrinkled colonies, LCB mount showing arthroconidia & blastoconidia and positive urease test help in its identification. In our study, the major risk factors for trichoporonosis were used central venous catheters and multiple antibiotics. Hence, strict infection control measures should be followed while handling patients with invasive medical devices. Higher mortality rate was observed because of its refractoriness to conventional antifungal drugs. Voriconazole should be used as drug of choice for treatment.




    Figures 1-3 and Tables 1 and 2 Courtesy Journal of Associationof Physicians of India

    For further reference log on to :


    http://japi.org/march_2019/03_oa_trichosporon%E2%80%93blood_stream.pdf
    Blood Stream InfectionfluconazoleimmunocompromiseditraconazoleJournal of Association of Physicians of IndiaLactophenol Cotton Blueopportunistic pathogenpatientsPD Hinduja National Hospitalphenotypic methodT asahiiThe Infectious Diseases Society of AmericaTrichosporonVoriconazole

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Hina Zahid
    Hina Zahid
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok